Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Sells $8,280,834.95 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Mayukh Sukhatme sold 689,495 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $12.01, for a total transaction of $8,280,834.95. Following the completion of the sale, the executive now owns 18,836,547 shares of the company’s stock, valued at approximately $226,226,929.47. The trade was a 3.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Tuesday, December 24th, Mayukh Sukhatme sold 185,946 shares of Roivant Sciences stock. The stock was sold at an average price of $12.00, for a total value of $2,231,352.00.
• On Wednesday, December 18th, Mayukh Sukhatme sold 412,584 shares of Roivant Sciences stock. The shares were sold at an average price of $12.05, for a total value of $4,971,637.20.

Roivant Sciences Stock Down 1.7 %

Roivant Sciences stock opened at $11.80 on Friday. The business has a 50 day moving average price of $11.91 and a two-hundred day moving average price of $11.53. Roivant Sciences Ltd. has a 12 month low of $9.69 and a 12 month high of $13.06. The stock has a market cap of $8.59 billion, a price-to-earnings ratio of 2.09 and a beta of 1.25.

Analyst Ratings Changes

A number of equities analysts have recently commented on ROIV shares. Bank of America lifted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.93.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ROIV. nVerses Capital LLC bought a new stake in Roivant Sciences in the 2nd quarter valued at $34,000. Gladius Capital Management LP bought a new stake in Roivant Sciences in the third quarter valued at about $35,000. Point72 Hong Kong Ltd acquired a new position in Roivant Sciences in the second quarter worth about $36,000. US Bancorp DE raised its position in Roivant Sciences by 146.5% in the third quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares in the last quarter. Finally, Quarry LP bought a new position in Roivant Sciences during the second quarter worth about $53,000. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.